U.S. Entertainment Stock News

Perspective Therapeutics revealed updated interim results from its Phase 1/2a trial of [212Pb]VMT-alpha-NET at ESMO Congress 2025, which sparked a sharp drop in the company’s share price as investors digested the latest efficacy signals. See our latest analysis for Perspective Therapeutics. This latest clinical trial update comes after a challenging year for Perspective Therapeutics. Following a brief rally in anticipation of new data, the 1-day share price return slipped by 2.5%, and the...

Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication. This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy. We'll explore how Fast Track status for AlloNK and...

Key Insights Significantly high institutional ownership implies Vir Biotechnology's stock price is sensitive to their...

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

With a price-to-earnings (or "P/E") ratio of 7x Dream Finders Homes, Inc. ( NYSE:DFH ) may be sending very bullish...

Nordic American Tankers (NYSE:NAT) has had a great run on the share market with its stock up by a significant 27% over...

As the Dow Jones Industrial Average reaches an all-time high amidst a flurry of corporate earnings reports, investors are keenly observing the broader U.S. market's performance against a backdrop of ongoing government shutdown and trade discussions with China. In this environment, identifying undervalued stocks becomes crucial for those looking to capitalize on potential opportunities that may arise from discrepancies between current stock prices and their intrinsic value.

Most readers would already be aware that Teekay's (NYSE:TK) stock increased significantly by 11% over the past three...

As the Dow Jones Industrial Average reaches an all-time high amid a flurry of robust earnings reports, the broader U.S. market is experiencing a wave of optimism despite ongoing economic challenges such as the government shutdown. In this environment, identifying stocks with strong fundamentals and growth potential can be particularly rewarding, especially as investors look beyond well-known names to uncover hidden opportunities within the market.

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

United States Lime & Minerals, Inc.'s ( NASDAQ:USLM ) price-to-earnings (or "P/E") ratio of 30.9x might make it look...

We can readily understand why investors are attracted to unprofitable companies. For example, Palladyne AI...

With a price-to-earnings (or "P/E") ratio of 4.2x MV Oil Trust ( NYSE:MVO ) may be sending very bullish signals at the...

Key Insights Institutions' substantial holdings in Axogen implies that they have significant influence over the...

Dorman Products, Inc. ( NASDAQ:DORM ), is not the largest company out there, but it led the NASDAQGS gainers with a...

Key Insights Insiders appear to have a vested interest in Waton Financial's growth, as seen by their sizeable ownership...

Key Insights Tecnoglass' estimated fair value is US$47.53 based on 2 Stage Free Cash Flow to Equity Tecnoglass is...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

There wouldn't be many who think BARK, Inc.'s ( NYSE:BARK ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...

The FDA’s acceptance of Replimune Group’s resubmitted Biologics License Application for RP1, combined with nivolumab, has sparked renewed optimism among investors. This regulatory milestone follows months of addressing agency feedback and signals real progress for the company’s advanced melanoma program. See our latest analysis for Replimune Group. The FDA's green light for Replimune's RP1 application sent the share price soaring nearly 99% in a single day, erasing months of slow declines and...

As the U.S. stock market begins the week on a high note, buoyed by gains across major indices and ongoing developments in trade and inflation data, investors are keenly observing opportunities amid economic uncertainties like the prolonged government shutdown. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential for growth, making it crucial to consider factors such as financial health and market position when evaluating investment...

On October 20, 2025, Safe Pro Group Inc. announced a private placement of 2,000,000 common shares at US$7 per share for gross proceeds of US$14,000,000, with Ondas Holdings Inc. as the lead new investor and expected closing on October 22, 2025, subject to standard conditions. In addition, Safe Pro Group recently filed a US$100 million shelf registration, opening the door to a broad range of potential future securities offerings that could support the company's funding needs. We'll explore...

At its 16th annual Jamf Nation User Conference in Denver earlier this month, Jamf announced the beta release of AI Analysis for Executive Threat Protection, an artificial intelligence-powered tool that accelerates and simplifies mobile forensic analysis for device security teams. This upgrade enables rapid incident response and translates complex forensic data into actionable steps, equipping organizations with more efficient tools to protect high-risk users without requiring specialized...

Artiva Biotherapeutics (ARTV) recently secured Fast Track Designation from the U.S. FDA for its AlloNK therapy in combination with rituximab, a treatment aimed at refractory rheumatoid arthritis. This recognition has captured significant market attention. See our latest analysis for Artiva Biotherapeutics. Artiva Biotherapeutics shares rocketed after news of the FDA Fast Track Designation, notching a remarkable 108.7% 1-month share price return and delivering 132.9% over the past 90 days...